Topotecan: An Oncologist's View
Open Access
- 1 December 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 3 (6) , 390-402
- https://doi.org/10.1634/theoncologist.3-6-390
Abstract
Topotecan (Hycamtin®) is a topoisomerase I inhibitor which demonstrated a wide spectrum of antitumor activity in preclinical models. During phase I assessment, evidence of activity was most promising...Keywords
This publication has 69 references indexed in Scilit:
- Phase I and pharmacologic study of topotecan in patients with impaired renal function.Journal of Clinical Oncology, 1996
- Clinical Pharmacokinetics of TopotecanClinical Pharmacokinetics, 1996
- Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic FunctionJNCI Journal of the National Cancer Institute, 1996
- Convergent approach to water soluble camptothecin derivativesBioorganic & Medicinal Chemistry Letters, 1995
- Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.Journal of Clinical Oncology, 1995
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitorAnnals of Oncology, 1993
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 daysAnti-Cancer Drugs, 1992
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991